Just a moment, the page is loading...
Browse ALL STUDIES
Keyword Search
View All Selected
Clear All
Login / Create Account
Login
Create Account
Home
About Us
Privacy Policy
Minimum System Requirements
How To Join
Mission
Data Sponsors
Researchers
How It Works
How to Request Data
Review of Requests
Data Sharing Agreement
Access to Data
Independent Review Panel
Metrics
FAQs
News
Help/Contact Us
Relationship between plasma levels of a1-Antitrypsin levels and the severity of airflow limitation
Proposal
2084
Title of Proposed Research
Relationship between plasma levels of a1-Antitrypsin levels and the severity of airflow limitation
Lead Researcher
Marc Miravitlles
Affiliation
Pneumology Department. Hospital Universitari Vall d'Hebron. Barcelona, Spain
Funding Source
None
Potential Conflicts of Interest
None
Data Sharing Agreement Date
26 April 2018
Lay Summary
Chronic Obstructive Pulmonary Disease (COPD) is a highly prevalent respiratory disease characterized by shortness of breath, cough, sputum production and frequent episodes of bronchitis, especially in winter months. COPD is also associated with other chronic diseases such as hypertension and other cardiovascular diseases.
The main cause of COPD is tobacco smoking, but not all smokers develop COPD and not all with the same degree of severity. Other factors have been implicated, such as the deficiency in one protein called a1-antitrypsin (AAT). Individuals with a deficiency of this protein have an increased risk of developing COPD at an earlier age because they lack the protective effect of AAT in the lungs.
However, the role of this protein in the development of COPD in patients not considered to have the deficiency is unknown. There have been only a few studies analysing the concentrations of this protein in healthy subjects and patients with COPD, but without the deficiency in AAT.
We think that data from the EPI SCAN study is a unique opportunity to analyse the possible role of the protein AAT as a risk factor for developing COPD in non-deficient individuals, or as a marker of disease severity, because the study collected data from a large sample of adults with and without COPD, smokers and non smokers and included blood analysis with quantification of AAT and other markers of inflammation.
We want to investigate the role of AAT in the development of COPD and identify if there are any predictors of the blood levels of this protein in adult individuals with and without COPD
Study Data Provided
[{ "PostingID": 1656, "Title": "GSK-107335", "Description": "COPD prevalence estimation in Spanish population." }]
Statistical Analysis Plan
Univariate differences in patient characteristics, lung function, indicators of metabolic and cardiac dysfunction, and inflammatory biomarkers according to the study groups will be evaluated using analysis of variance (ANOVA) for continuous variables or chi-square tests for dichotomous variables. In the case of heteroscedasticity the Kruskal-Wallis test will be used. Bivariate comparisons will be performed by Pearson correlations or t-test. To evaluate independent predictors of AAT blood levels, we will use multivariate linear regression analyses.
Publication Citation
https://www.archbronconeumol.org/en-serum-levels-alpha1-antitrypsin-their-relationship-articulo-S1579212920300100
DOI: 10.1016/j.arbres.2019.03.001
© 2024 ideaPoint. All Rights Reserved.
Powered by ideaPoint.
Help
Privacy Policy
Cookie Policy
Help and Resources